시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 삼중음성 유방암(TNBC) 시장 보고서(2025년)
Triple Negative Breast Cancer Global Market Report 2025
상품코드 : 1720915
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,301,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,108,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,914,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

삼중음성 유방암(TNBC) 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 유방암 발생 증가, 삼중음성 유방암 발생 증가, 의료 인프라 확충, 연구개발 활동 증가, HER2 양성 유방암의 증례 증가 등에 기인한다고 생각됩니다.

의료시설의 진보가 삼중음성 유방암(TNBC)시장의 성장을 가속할 것으로 예측됩니다. 병원, 클리닉, 진단 센터를 포함한 의료 시설은 환자에게 의료 서비스를 제공합니다. 건강 관리 인프라의 개선은 투자 증가, 환자 중심의 관리의 중시, 인구 증가, 인구 역학의 고령화에 기인합니다. 치료, 집학 케어 팀, 환자 교육 개선에 대한 액세스를 제공함으로써 TNBC 치료를 지원하여 조기 발견, 치료 결과, 생존율 향상으로 이어집니다. 미국 의료 협회는 미국 병원 수가 전년 6,093개에서 6,129개로 0.591% 증가했다고 보고했습니다.

TNBC 시장의 주요 기업은 암 치료의 특이성과 효능을 향상시키기 위해 저분자 의약품 등의 혁신적 치료법의 개발에 주력하고 있습니다. 미국 임상 단계 생명공학 회사인 Lantern Pharma Inc.는 2024년 12월, TNBC 치료를 위한 연구 약물 후보 LP-184를 발표했습니다. 미국 식품의약국(FDA)은 DNA 손상 복구 경로에 특정 바이오마커와 돌연변이를 가진 암세포의 DNA를 선택적으로 손상하도록 설계된 차세대 아실플루벤과 저분자제인 LP-18 AI 플랫폼은 치료에 반응할 가능성이 높은 환자 집단과 암 아형을 식별하는 데 도움을 줍니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Triple-negative breast cancer (TNBC) is an aggressive and rapidly growing subtype of breast cancer that lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2), making it unresponsive to hormonal therapies or HER2-targeted treatments. Compared to other breast cancer types, TNBC is more challenging to treat and has a higher recurrence rate. It is more prevalent in younger women, African American women, and individuals with BRCA1 mutations, highlighting its genetic predisposition.

The primary treatment options for TNBC include chemotherapy, immunotherapy, targeted therapy, surgery, radiation therapy, and other approaches. Chemotherapy works by using drugs to destroy cancer cells or inhibit their growth. Diagnosis involves various tests, such as imaging techniques, assays, and breast biopsies. These treatments and diagnostic methods are utilized by hospitals, specialty clinics, ambulatory surgical centers, and other healthcare facilities.

The triple-negative breast cancer market research report is one of a series of new reports from The Business Research Company that provides triple-negative breast cancer market statistics, including triple-negative breast cancer industry global market size, regional shares, competitors with a triple-negative breast cancer market share, detailed triple-negative breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the triple-negative breast cancer industry. This triple-negative breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The triple negative breast cancer market size has grown strongly in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the rising number of women, increasing demand for TNBC treatments, greater awareness of early breast cancer detection, a growing patient population, and increased healthcare spending.

The triple negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to the rising cases of breast cancer, the growing incidence of triple-negative breast cancer, expanding healthcare infrastructure, increasing research and development activities, and the rising cases of HER2-positive breast cancer. Key trends during this period include innovative TNBC treatments, advancements in radiation techniques, improvements in diagnostic technology, increasing demand for personalized medicine, and ongoing product innovation.

The advancement of healthcare facilities is expected to drive the growth of the triple-negative breast cancer (TNBC) market. Healthcare facilities, including hospitals, clinics, and diagnostic centers, provide medical care and services to patients. Improvements in healthcare infrastructure result from increased investment, a focus on patient-centered care, population growth, and aging demographics. Enhanced healthcare facilities support TNBC treatment by offering access to advanced diagnostic technologies, personalized therapies, multidisciplinary care teams, and improved patient education, leading to better early detection, treatment outcomes, and survival rates. For example, in May 2023, the American Health Care Association reported that the number of hospitals in the United States increased by 0.591%, from 6,093 in the previous year to 6,129. As a result, the improvement of healthcare facilities is fueling the growth of the TNBC market.

Leading companies in the TNBC market are focused on developing innovative treatments, such as small molecule drugs, to improve the specificity and effectiveness of cancer therapies. Small molecule drugs are low molecular weight compounds capable of penetrating cells to modulate biological processes, making them effective against cancer and other diseases. For instance, in December 2024, Lantern Pharma Inc., a US-based clinical-stage biotechnology company, announced the investigational drug candidate LP-184 for TNBC treatment. The U.S. Food and Drug Administration (FDA) granted Fast Track designation for LP-184, a next-generation acylfulvene and small molecule drug designed to selectively damage DNA in cancer cells with specific biomarkers or mutations in DNA damage repair pathways. Lantern's proprietary RADR AI platform helps identify patient populations and cancer subtypes likely to respond to the treatment. LP-184 is currently being evaluated across multiple solid tumors and has demonstrated nanomolar potency, showing promise in drug-resistant cancers and advancing targeted cancer therapy.

In December 2024, Galera Therapeutics Inc., a US-based biopharmaceutical company, acquired Nova Pharmaceuticals Inc. to advance its clinical development efforts. This acquisition enables Galera to further explore its inhibitor's potential in treating TNBC. Nova Pharmaceuticals Inc. is a US-based clinical-stage biotechnology company specializing in developing novel treatments for triple-negative and metaplastic breast cancer.

Major players in the triple negative breast cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Novartis AG, Fresenius Kabi AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Illumina Inc., Bio-Rad Laboratories Inc., Seagen Inc., MacroGenics Inc., Immutep Limited, G1 Therapeutics Inc., Galera Therapeutics Inc., HiberCell Inc., Infinity Pharmaceuticals Inc.

North America was the largest region in the triple negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in triple-negative breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the triple-negative breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The triple-negative breast cancer market consists of revenues earned by entities by providing services such as diagnostic testing, biomarker analysis, drug development and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The triple-negative breast cancer market also includes sales of genetic testing kits, companion diagnostic tests, radiopharmaceuticals and clinical trial drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Triple Negative Breast Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on triple negative breast cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for triple negative breast cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The triple negative breast cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Triple Negative Breast Cancer Market Characteristics

3. Triple Negative Breast Cancer Market Trends And Strategies

4. Triple Negative Breast Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Triple Negative Breast Cancer Growth Analysis And Strategic Analysis Framework

6. Triple Negative Breast Cancer Market Segmentation

7. Triple Negative Breast Cancer Market Regional And Country Analysis

8. Asia-Pacific Triple Negative Breast Cancer Market

9. China Triple Negative Breast Cancer Market

10. India Triple Negative Breast Cancer Market

11. Japan Triple Negative Breast Cancer Market

12. Australia Triple Negative Breast Cancer Market

13. Indonesia Triple Negative Breast Cancer Market

14. South Korea Triple Negative Breast Cancer Market

15. Western Europe Triple Negative Breast Cancer Market

16. UK Triple Negative Breast Cancer Market

17. Germany Triple Negative Breast Cancer Market

18. France Triple Negative Breast Cancer Market

19. Italy Triple Negative Breast Cancer Market

20. Spain Triple Negative Breast Cancer Market

21. Eastern Europe Triple Negative Breast Cancer Market

22. Russia Triple Negative Breast Cancer Market

23. North America Triple Negative Breast Cancer Market

24. USA Triple Negative Breast Cancer Market

25. Canada Triple Negative Breast Cancer Market

26. South America Triple Negative Breast Cancer Market

27. Brazil Triple Negative Breast Cancer Market

28. Middle East Triple Negative Breast Cancer Market

29. Africa Triple Negative Breast Cancer Market

30. Triple Negative Breast Cancer Market Competitive Landscape And Company Profiles

31. Triple Negative Breast Cancer Market Other Major And Innovative Companies

32. Global Triple Negative Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Triple Negative Breast Cancer Market

34. Recent Developments In The Triple Negative Breast Cancer Market

35. Triple Negative Breast Cancer Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기